Edition:
United Kingdom

Xenon Pharmaceuticals Inc (XENE.OQ)

XENE.OQ on NASDAQ Stock Exchange Global Market

10.64USD
16 Oct 2018
Change (% chg)

$0.38 (+3.70%)
Prev Close
$10.26
Open
$10.28
Day's High
$10.64
Day's Low
$10.28
Volume
4,553
Avg. Vol
38,789
52-wk High
$15.90
52-wk Low
$2.15

Chart for

About

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment... (more)

Overall

Beta: --
Market Cap(Mil.): $54.00
Shares Outstanding(Mil.): 18.00
Dividend: --
Yield (%): --

Financials

  XENE.OQ Industry Sector
P/E (TTM): -- 86.20 32.69
EPS (TTM): -1.67 -- --
ROI: -55.45 0.73 14.32
ROE: -55.50 1.82 16.04

BRIEF-Xenon Pharmaceuticals Q1 Net Loss Per Common Share $0.21

* XENON PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

08 May 2018

BRIEF-Xenon Pharmaceuticals Enters Into At-The-Market Equity Offering Sales Agreement With Stifel, Nicolaus & Co

* XENON PHARMACEUTICALS INC - ON MAY 8, CO ENTERED INTO AN AT--MARKET EQUITY OFFERING SALES AGREEMENT WITH STIFEL, NICOLAUS & COMPANY - SEC FILING

08 May 2018

BRIEF-Xenon Pharmaceuticals To Host Conference Call To Discuss Q1 2018 Financial Results

* XENON PHARMACEUTICALS TO HOST CONFERENCE CALL AND WEBCAST TO DISCUSS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE Source text for Eikon: Further company coverage:

01 May 2018

Earnings vs. Estimates